APOTREM
ActiveSummary
The annual accounts of APOTREM for financial year 2025 show a net loss of 73% of total assets. The 2025 annual accounts show equity of €18,824 and a net result of -€80,844. Equity is shrinking by about 22% per year and would, assuming unchanged policy, indicatively turn negative around financial year 2026. Its solvency ranks better than 37% of 1,816 sector peers (NACE 77, financial year 2025). The company has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 1.2% (low).
History
Acts, filings and financial milestones
06-01
Gazette deed
Resignation: Louis Van Tendeloo (director)Appointments: GIURA PHARMA (director) and PHARMA DEPRÉE (director) · Permanent representatives: Caroline Caenepeel and Inne Deprée · Registered-office move10 facts ▸
- General meeting, 15-12-2025
- Director resignation, Louis Van Tendeloo (director)
- Director appointment, GIURA PHARMA (director)
- Director in office, Caroline Caenepeel (sole director)
- Permanent representative, Caroline Caenepeel
- Director appointment, PHARMA DEPRÉE (director)
- Director in office, Inne Deprée (sole director)
- Permanent representative, Inne Deprée
- Board meeting, 15-12-2025
- Registered-office move, 3120 Tremelo, Kruisstraat 175
11-12
Gazette deed
MiscellaneousCapital increase · Bank account · Declaration5 facts ▸
- General meeting, 27-11-2025
- Capital increase, €313,000 (2 times)
- Bank account, “bijzondere rekening, integraal gestort” (deed in Dutch)
- Declaration, “no obligation to prepare reports, geen nieuwe aandelen worden uitgegeven” (deed in Dutch)
- Power of attorney
About the unread acts
Of the 5 Belgian Official Gazette deeds we know for this company, 2 have been read. The other 3 have not been read yet: what they contain is neither established nor disproved here.